Amendments to the Claims:

This listing of claims will replace all prior versions and listing of claims in the application.

Please cancel claims 1 to 13 without prejudice or disclaimer.

Please add new claims 14 to 30 as shown.

Claims 1 to 13. (cancelled)

Claim 14. (new): A modified release pharmaceutical composition comprising a pharmaceutically acceptable salt of a compound of formula (I) as active ingredient



(I)

wherein:

$\mathbf{R^1}$ is $-CHF_2$ or $-CH_2CH_2F$;

$\mathbf{R^2}$ is hydrogen, hydroxy, methoxy or ethoxy; and

n is 0 or 2; and

at least one gelling polymer selected from hydroxymethylcellulose (HMC), hydroxyethylcellulose (HEC), hydroxypropylcellulose (HPC), methylcellulose (MC), ethylcellulose (EC), carboxyethylcellulose (CEC), ethylhydroxyethylcellulose (EHEC), carboxymethylhydroxyethylcellulose (CMHEC), hydroxypropylmethylcellulose (HPMC), hydroxypropylethylcellulose (HPEC) and sodium carboxymethylcellulose (Na CMC).

Claim 15. (new): The composition according to claim 14 wherein the gelling polymer comprises HPC and HPMC.

Claim 16. (new): The composition according to claim 15 wherein the HPMC is present in about 30 to about 80 percent w/w.

Claim 17. (new): The composition according to claim 14 wherein the gelling polymer comprises HPC and EC.

Claim 18. (new): The composition according to claim 17 wherein the HPC is present in about 10 to about 95 percent w/w.

Claim 19. (new): The composition according to claim 17 wherein the HPC is present in about 30 to about 80 percent w/w.

Claim 20. (new): The composition according to any one of claims 14, 15 and 17 further comprising at least one pharmaceutically acceptable diluent and/or lubricant.

Claim 21. (new): The composition according to claim 20 wherein the pharmaceutically acceptable diluent and/or lubricant is selected from calcium phosphate, lactose, microcrystalline cellulose, mannitol, sorbitol, titanium dioxide, aluminum silicate, magnesium stearate, sodium stearyl fumarate and mixtures thereof.

Claim 22. (new): The composition according to claim 14 wherein the active ingredient is a pharmaceutically acceptable salt of
Ph(3-Cl)(5-$OCHF_2$)-(R)CH(OH)C(O)-(S)Aze-Pab(OMe);
Ph(3-Cl)(5-$OCHF_2$)-(R)CH(OH)C(O)-(S)Aze-Pab(2,6-diF)(OMe); or
Ph(3-Cl)(5-OCH_2CH_2F)-(R)CH(OH)C(O)-(S)Aze-Pab(OMe).

Claim 23. (new): The composition according to claim 22 wherein the pharmaceutically acceptable salt is crystalline.

Claim 24. (new): The composition according to any one of claims 14, 22 and 23 wherein the pharmaceutically acceptable salt is an acid addition salt, wherein the acid of the acid addition salt is

selected from the group consisting of ethanesulfonic acid, n-propanesulfonic acid, benzenesulfonic acid, 1,5-naphthalenedisulfonic acid and n-butanesulfonic acid.

Claim 25. (new): The composition according to claim 24 wherein the active ingredient is benzenesulfonic acid salt of Ph(3-Cl)(5-$OCHF_2$)-(R)CH(OH)C(O)-(S)Aze-Pab(OMe) characterised by an X-ray powder diffraction pattern characterised by peaks with d-values at 5.9, 4.73, 4.09 and 4.08Å.

Claim 26. (new): The composition according to claim 24 wherein the active ingredient is hemi-1,5-naphthalenedisulfonic acid salt of Ph(3-Cl)(5-$OCHF_2$)-(R)CH(OH)C(O)-(S)Aze-Pab(2,6-diF)(OMe) characterised by an X-ray powder diffraction pattern characterised by peaks with d-values at 18.3, 9.1, 5.6, 5.5, 4.13, 4.02, 3.86, 3.69 and 3.63Å.

Claim 27. (new): The composition according to claim 14 further comprising iota-carrageenan.

Claim 28. (new): The composition according to claim 14 further comprising sodium dodecyl sulphate (SDS).

Claim 29. (new): The composition according to claim 14 wherein the composition is formulated as a gel matrix.

Claim 30. (new): A method of treating a cardiovascular disorder in a patient suffering from said disorder comprising administrating to the patient a therapeutically effective amount of a composition according to claim 14.